Prediction of response to ESAs in anemic MDS patients is often based on clinical biomarkers such as volume of RBC transfusion, serum EPO levels, ferritin, and IPSS/IPSS-R [18], and the use of Nordic score combined with serum EPO levels and transfusion volume has also been proposed [19]. Here, EPO is linked to myelodysplastic syndrome.